TY - JOUR
T1 - Small-molecule-based regulation of RNA-delivered circuits in mammalian cells
AU - Wagner, Tyler E.
AU - Becraft, Jacob R.
AU - Bodner, Katie
AU - Teague, Brian
AU - Zhang, Xin
AU - Woo, Amanda
AU - Porter, Ely
AU - Alburquerque, Bremy
AU - Dobosh, Brian
AU - Andries, Oliwia
AU - Sanders, Niek N.
AU - Beal, Jacob
AU - Densmore, Douglas
AU - Kitada, Tasuku
AU - Weiss, Ron
N1 - Publisher Copyright:
© 2018, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Synthetic mRNA is an attractive vehicle for gene therapies because of its transient nature and improved safety profile over DNA. However, unlike DNA, broadly applicable methods to control expression from mRNA are lacking. Here we describe a platform for small-molecule-based regulation of expression from modified RNA (modRNA) and self-replicating RNA (replicon) delivered to mammalian cells. Specifically, we engineer small-molecule-responsive RNA binding proteins to control expression of proteins from RNA-encoded genetic circuits. Coupled with specific modRNA dosages or engineered elements from a replicon, including a subgenomic promoter library, we demonstrate the capability to externally regulate the timing and level of protein expression. These control mechanisms facilitate the construction of ON, OFF, and two-output switches, with potential therapeutic applications such as inducible cancer immunotherapies. These circuits, along with other synthetic networks that can be developed using these tools, will expand the utility of synthetic mRNA as a therapeutic modality.
AB - Synthetic mRNA is an attractive vehicle for gene therapies because of its transient nature and improved safety profile over DNA. However, unlike DNA, broadly applicable methods to control expression from mRNA are lacking. Here we describe a platform for small-molecule-based regulation of expression from modified RNA (modRNA) and self-replicating RNA (replicon) delivered to mammalian cells. Specifically, we engineer small-molecule-responsive RNA binding proteins to control expression of proteins from RNA-encoded genetic circuits. Coupled with specific modRNA dosages or engineered elements from a replicon, including a subgenomic promoter library, we demonstrate the capability to externally regulate the timing and level of protein expression. These control mechanisms facilitate the construction of ON, OFF, and two-output switches, with potential therapeutic applications such as inducible cancer immunotherapies. These circuits, along with other synthetic networks that can be developed using these tools, will expand the utility of synthetic mRNA as a therapeutic modality.
UR - https://www.scopus.com/pages/publications/85055054874
U2 - 10.1038/s41589-018-0146-9
DO - 10.1038/s41589-018-0146-9
M3 - Article
C2 - 30327560
AN - SCOPUS:85055054874
SN - 1552-4450
VL - 14
SP - 1043
EP - 1050
JO - Nature Chemical Biology
JF - Nature Chemical Biology
IS - 11
ER -